Press Releases, Annual Reports and Proxy Statements

2010

	1/12/10 - Aeolus Pharmaceuticals Invited to Submit Full Proposal to BARDA for AEOL 10150 as a Potential Medical Countermeasure for Pulmonary Injury Associated with Acute Radiation Syndrome and Delayed Effects of Acute Radiation Exposure
2009
	12/28/09 - Aeolus Pharmaceuticals Form 10-K for the fiscal year ended September 30, 2009
	12/28/09 - Aeolus Pharmaceuticals Announces Fiscal Year 2009 Financial Results
	12/17/09 - Aeolus Pharmaceuticals’ AEOL 11207 Subect of Research Grant from Michael J. Fox Foundation
	11/17/09 - Duke University Initiates Study of AEOL 10150 to Measure Compound’s Ability to Protect Healthy Tissue in Mice Receiving Chemotherapy and Radiation for Non-Small Cell Lung Cancer
	11/05/09 - Data Demonstrating Aeolus Pharmaceuticals’ AEOL 10150’s Efficacy as a Broad Spectrum Countermeasure Against Radiological and Chemical Threats Presented at the GHSI Public Health Emergency Medical Countermeasures Workshop
	11/4/09 - Aeolus Pharmaceuticals’ AEOL 10150 Protects Lungs Against Chlorine Gas Exposure in Animal Studies
	10/22/09 - Aeolus Pharmaceuticals’ AEOL 10150 Protects Lungs Against Mustard Gas Exposure in Animal Studies
	10/15/09 - Animal Data Demonstrating Aeolus Pharmaceuticals’ AEOL 10150’s Efficacy in Mitigating Radiation Damage to the Lung Presented at the 55th Annual Meeting of the Radiation Research Society
	10/7/09 - Aeolus Pharmaceuticals’ AEOL 10150 Protects Lungs Against Mustard Gas Exposure in Animal Studies
	10/6/09 - Aeolus Pharmaceuticals Completes $1.65 Million Financing, Converts $1 Million in Debt to Common Stock and Receives an Option to Raise Additional $1.65 Million
	9/14/09 - Aeolus Pharmaceuticals Initiates Second Study of AEOL 10150 as a Countermeasure to Radiation Exposure in Mice
	9/11/09 - Aeolus Pharmaceuticals Submits White Paper to BARDA For Funding of AEOL 10150 as a Countermeasure to Lung Injury Due to Radiation Exposure
	9/08/09 - Aeolus Pharmaceuticals Initiates Study of AEOL 10150 as a Countermeasure to Radiation Exposure in Non-Human Primates
	7/31/09 - Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2009 Financial Results
	7/06/09 - Aeolus Pharmaceuticals’ AEOL 10150 Significantly Increases Survival in Mice Exposed to Radiation when Administered After Exposure
	6/3/09 - National Institutes of Health’s National Institute for Allergy and Infectious Diseases Initiates Study of Aeolus Pharmaceutical Drug as a Countermeasure for Radiation Exposure
	5/01/09 - Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2009 Financial Results
	3/31/09 - Aeolus Pharmaceuticals Completes $1.5 Million Financing
	2/09/09 - NIH CounterACT Program Begins Studies of Aeolus Pharmaceuticals’ AEOL 10150 as a Countermeasure to Sulfur Mustard Gas Exposure
	2/6/09 - Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2009 Financial Results
	1/28/09 - Proxy Statement for Aeolus Pharmaceuticals Annual Meeting of Shareholders to be held on March 26, 2009
2008
	12/12/08 - Aeolus Pharmaceuticals Form 10-K for the fiscal year ended September 30, 2008
	12/12/08 - Aeolus Pharmaceuticals Announces Fiscal Year 2008 Financial Results
	12/02/08 - Aeolus Pharmaceuticals Completes Fifth Closing of Senior Convertible Debt Financing
	11/21/08 - Aeolus Pharmaceuticals’ Initiates Pivotal Animal Study of AEOL 10150 as a Countermeasure to Radiation Exposure
	11/04/08 - Aeolus Pharmaceuticals Completes Fourth Closing of Senior Convertible Debt Financing
	10/02/08 - Aeolus Pharmaceuticals Completes Third Closing of Senior Convertible Debt Financing
	10/01/08 - Aeolus Pharmaceuticals’ Receives $175,000 Milestone Payment from Cardiovascular Company
	09/30/08 - Aeolus Pharmaceuticals’ Announces Initiation of Multiple Dose Study of AEOL 10150 in a Patient with ALS
	09/05/08 - Aeolus Pharmaceuticals Completes Second Closing of Senior Convertible Debt Financing
	08/04/08 - Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2008 Finanial Results
	08/01/08 - Aeolus Pharmaceuticals Completes Senior Convertible Debt Financing
	05/09/08 - Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2008 Finanial Results
	04/23/08 - Aeolus Pharmaceuticals’ AEOL 10150 Provides Significant Protection of Lungs and Skin in Animal Studies of Mustard Gas Exposure
	04/15/08 - Aeolus Pharmaceuticals’ AEOL 10150 Protects Lungs from Fractionated Radiation; Reduces Angiogenesis and Inflammation
	02/06/08 - Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2008 Financial Results
2007
	12/13/07 - Aeolus Pharmaceuticals Announces Fiscal Year 2007 Financial Results
	11/07/07 - Aeolus Pharmaceuticals’ AEOL 10150 Protects Lungs Against Mustard Gas
	11/05/07 - Aeolus Pharmaceuticals Provides Update on Pipeline Development Program
	10/30/07 - Aeolus Pharmaceuticals to Present at Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference
	07/30/07 - Aeolus Pharmaceuticals Announces Third Quarter Financial Results
	05/23/07 - Aeolus Pharmaceuticals Lead Compound to Be Tested in NIH Sponsored Mustard Gas Treatment Study
	05/22/07 - Aeolus Pharmaceuticals Completes $2.0 Million Financing from New Institutional Investors
	05/10/07 - Aeolus Pharmaceuticals Announces Second Quarter Financial Results
	04/26/07 - Study Demonstrating Aeolus Compound's Neuroprotection in Parkinson's Disease Published in the Journal of Neuroscience
	04/23/07 - Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
	04/20/07 - Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential to Accelerate Recovery of Bone Marrow Stem Cells Following Cancer Radiation Therapy
	04/19/07 - Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
	04/18/07 - Aeolus Pharmaceuticals' AEOL 10150 Highlighted in Nature Genetics Publication
	03/22/07 - Aeolus Pharmaceuticals Announces Successful Completion of Multiple Dose Safety Study of AEOL 10150
	02/08/07 - Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2007 Financial Results

2008

	12/12/08 - Aeolus Pharmaceuticals Form 10-K for the fiscal year ended September 30, 2008
	1/28/09 - Proxy Statement for Aeolus Pharmaceuticals Annual Meeting of Shareholders to be held on March 26, 2009
	12/12/08 - Aeolus Pharmaceuticals Form 10-K for the fiscal year ended September 30, 2008
	12/12/08 - Aeolus Pharmaceuticals Announces Fiscal Year 2008 Financial Results
	12/02/08 - Aeolus Pharmaceuticals Completes Fifth Closing of Senior Convertible Debt Financing
	11/21/08 - Aeolus Pharmaceuticals’ Initiates Pivotal Animal Study of AEOL 10150 as a Countermeasure to Radiation Exposure
	11/04/08 - Aeolus Pharmaceuticals Completes Fourth Closing of Senior Convertible Debt Financing
	10/02/08 - Aeolus Pharmaceuticals Completes Third Closing of Senior Convertible Debt Financing
	10/01/08 - Aeolus Pharmaceuticals’ Receives $175,000 Milestone Payment from Cardiovascular Company
	09/30/08 - Aeolus Pharmaceuticals’ Announces Initiation of Multiple Dose Study of AEOL 10150 in a Patient with ALS
	09/05/08 - Aeolus Pharmaceuticals Completes Second Closing of Senior Convertible Debt Financing
	08/04/08 - Aeolus Pharmaceuticals Announces Third Quarter Fiscal Year 2008 Finanial Results
	08/01/08 - Aeolus Pharmaceuticals Completes Senior Convertible Debt Financing
	05/09/08 - Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2008 Finanial Results
	04/23/08 - Aeolus Pharmaceuticals’ AEOL 10150 Provides Significant Protection of Lungs and Skin in Animal Studies of Mustard Gas Exposure
	04/15/08 - Aeolus Pharmaceuticals’ AEOL 10150 Protects Lungs from Fractionated Radiation; Reduces Angiogenesis and Inflammation
	02/06/08 - Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2008 Financial Results
2007
	12/13/07 - Aeolus Pharmaceuticals Announces Fiscal Year 2007 Financial Results
	11/07/07 - Aeolus Pharmaceuticals’ AEOL 10150 Protects Lungs Against Mustard Gas
	11/05/07 - Aeolus Pharmaceuticals Provides Update on Pipeline Development Program
	10/30/07 - Aeolus Pharmaceuticals to Present at Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference
	07/30/07 - Aeolus Pharmaceuticals Announces Third Quarter Financial Results
	05/23/07 - Aeolus Pharmaceuticals Lead Compound to Be Tested in NIH Sponsored Mustard Gas Treatment Study
	05/22/07 - Aeolus Pharmaceuticals Completes $2.0 Million Financing from New Institutional Investors
	05/10/07 - Aeolus Pharmaceuticals Announces Second Quarter Financial Results
	04/26/07 - Study Demonstrating Aeolus Compound's Neuroprotection in Parkinson's Disease Published in the Journal of Neuroscience
	04/23/07 - Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
	04/20/07 - Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential to Accelerate Recovery of Bone Marrow Stem Cells Following Cancer Radiation Therapy
	04/19/07 - Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
	04/18/07 - Aeolus Pharmaceuticals' AEOL 10150 Highlighted in Nature Genetics Publication
	03/22/07 - Aeolus Pharmaceuticals Announces Successful Completion of Multiple Dose Safety Study of AEOL 10150
	02/08/07 - Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2007 Financial Results

2006

	12/15/06 - Aeolus Pharmaceuticals Announces Fiscal Year 2006 Financial Results
	10/24/06 - Aeolus Pharmaceuticals Secures European Patents for AEOL 10150 and Pipeline Compounds
	08/11/06 - Aeolus Pharmaceuticals Announces Third Quarter Earnings
	07/21/06 - Zangani Investor Community Announces Interview with Aeolus Pharmaceuticals, Inc. President John McManus
	06/20/06 - Aeolus Pharmaceuticals Selects AEOL 11207 as First Pipeline Development Candidate
	06/06/06 - Aeolus Pharmaceuticals Completes $5.0 Million Financing from New Institutional Investors
	05/12/06 - Aeolus Pharmaceuticals Announces Second Quarter Financial Results
	03/13/06 - Aeolus Pharmaceuticals Receives $350,000 Milestone Payment and Equity Interest from Cardiovascular Company
	02/16/06 - Aeolus Pharmaceuticals Announces First Quarter Earnings

2005

	12/27/05 - Aeolus Pharmaceuticals Announces Fiscal Year 2005 Financial Results
	12/08/05 - AEOL 10150 Clinical Data in ALS Patients To be Presented at the 16th International Symposium on ALS/MND
	11/30/05 - Aeolus Pharmaceuticals Announces Completion of Dosing of First Multiple Dose Cohort of AEOL 10150 in ALS Patients
	11/03/05 - Aeolus Pharmaceuticals to Present at Rodman and Renshaw Techvest 7th Annual Healthcare Conference
	10/24/05 - Aeolus Pharmaceuticals Announces Addition of New Board Member, John Farah of Cephalon, Inc.
	10/19/05 - Aeolus Pharmaceuticals Announces Initiation of Multiple Dose Study of AEOL 10150 in Patients with Lou Gehrig’s Disease
	10/18/05 - Protection of Normal Tissue from Radiation-Induced Injury Using AEOL 10150 Presented at the Annual Meeting of the American Society for Therapeutic Radiology and Oncology
	10/12/05 - Aeolus Pharmaceuticals to Present at Bio InvestorForum 2005
	09/30/05 - 10K Filing
	09/20/05 - Parkinson’s Disease Data From the Aeolus Pharmaceuticals Pipeline Initiative to be Presented at Neuroscience 2005 and The Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson’s Disease and Other Movement Disorders
	09/07/05 - Aeolus Pharmaceuticals Reports Positive Safety Results from Completed Phase 1 Single Dose Study of AEOL 10150 in 25 Patients with ALS (Lou Gehrig’s Disease)
	09/01/05 - Aeolus Pharmaceuticals, Inc. Announces Relocation of Headquarters and Operations to Southern California
	08/04/05 - Aeolus Pharmaceuticals, Inc. Announces Publication of Results of AEOL 10150 Studies in Annals of Neurology
	08/03/05 - Aeolus Pharmaceuticals Announces Third Quarter Financial Results
	06/30/05 - Aeolus Pharmaceuticals, Inc. Retains ThinkEquity Partners LLC for Counsel and Assistance with Strategic Opportunities
	06/27/05 - Aeolus Pharmaceuticals, Inc. Announces Capital Infusion from Existing Shareholders
	06/21/05 - Aeolus Pharmaceuticals, Inc. Announces Strategic Enhancement of Management Team